BioVie (BIVI) Competitors $0.89 +0.05 (+6.43%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BIVI vs. JSPR, IVVD, VHAQ, INZY, ALTS, CLSD, VTVT, BMEA, ACHL, and BDRXShould you be buying BioVie stock or one of its competitors? The main competitors of BioVie include Jasper Therapeutics (JSPR), Invivyd (IVVD), Viveon Health Acquisition (VHAQ), Inozyme Pharma (INZY), Janone (ALTS), Clearside Biomedical (CLSD), vTv Therapeutics (VTVT), Biomea Fusion (BMEA), Achilles Therapeutics (ACHL), and Biodexa Pharmaceuticals (BDRX). These companies are all part of the "pharmaceutical products" industry. BioVie vs. Jasper Therapeutics Invivyd Viveon Health Acquisition Inozyme Pharma Janone Clearside Biomedical vTv Therapeutics Biomea Fusion Achilles Therapeutics Biodexa Pharmaceuticals BioVie (NASDAQ:BIVI) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, community ranking, dividends, earnings, profitability, valuation and institutional ownership. Do insiders and institutionals hold more shares of BIVI or JSPR? 4.6% of BioVie shares are held by institutional investors. Comparatively, 79.8% of Jasper Therapeutics shares are held by institutional investors. 4.0% of BioVie shares are held by company insiders. Comparatively, 2.7% of Jasper Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate BIVI or JSPR? BioVie presently has a consensus price target of $3.00, indicating a potential upside of 243.64%. Jasper Therapeutics has a consensus price target of $62.50, indicating a potential upside of 1,196.68%. Given Jasper Therapeutics' higher possible upside, analysts plainly believe Jasper Therapeutics is more favorable than BioVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Jasper Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BIVI or JSPR more profitable? Jasper Therapeutics' return on equity of -67.64% beat BioVie's return on equity.Company Net Margins Return on Equity Return on Assets BioVieN/A -134.07% -93.44% Jasper Therapeutics N/A -67.64%-58.53% Which has more volatility & risk, BIVI or JSPR? BioVie has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.55, suggesting that its share price is 155% more volatile than the S&P 500. Does the MarketBeat Community believe in BIVI or JSPR? Jasper Therapeutics received 28 more outperform votes than BioVie when rated by MarketBeat users. Likewise, 90.20% of users gave Jasper Therapeutics an outperform vote while only 66.67% of users gave BioVie an outperform vote. CompanyUnderperformOutperformBioVieOutperform Votes1866.67% Underperform Votes933.33% Jasper TherapeuticsOutperform Votes4690.20% Underperform Votes59.80% Does the media prefer BIVI or JSPR? In the previous week, BioVie had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 1 mentions for BioVie and 0 mentions for Jasper Therapeutics. BioVie's average media sentiment score of 0.00 equaled Jasper Therapeutics'average media sentiment score. Company Overall Sentiment BioVie Neutral Jasper Therapeutics Neutral Which has better valuation & earnings, BIVI or JSPR? Jasper Therapeutics is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioVieN/AN/A-$32.12M-$9.76-0.09Jasper TherapeuticsN/AN/A-$64.46M-$4.86-0.99 SummaryJasper Therapeutics beats BioVie on 9 of the 15 factors compared between the two stocks. Get BioVie News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIVI vs. The Competition Export to ExcelMetricBioViePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.11M$6.58B$5.41B$7.70BDividend YieldN/A3.21%5.44%4.33%P/E Ratio-0.097.1122.2418.31Price / SalesN/A266.19394.02105.72Price / CashN/A65.6738.2034.62Price / Book0.346.426.784.23Net Income-$32.12M$142.49M$3.21B$247.51M7 Day Performance3.83%7.59%5.03%5.68%1 Month Performance-26.02%-8.08%-6.18%-4.10%1 Year Performance72.73%-1.74%16.18%4.41% BioVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIVIBioVie1.3195 of 5 stars$0.89+6.4%$3.00+235.5%+70.8%$16.50MN/A-0.0910JSPRJasper Therapeutics1.5195 of 5 stars$4.20+1.0%$62.50+1,388.1%-79.4%$63.09MN/A-0.8920Positive NewsIVVDInvivyd2.7726 of 5 stars$0.53-4.4%$7.52+1,331.5%-71.6%$62.99M$25.38M-0.27100VHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading VolumeINZYInozyme Pharma2.9053 of 5 stars$0.97+9.4%$14.63+1,409.1%-77.7%$62.26MN/A-0.6250Positive NewsALTSJanoneN/A$3.85flatN/AN/A$61.90M$12.53M0.00170CLSDClearside Biomedical2.9127 of 5 stars$0.80+4.6%$5.25+556.2%-41.9%$61.83M$1.66M-1.7830Positive NewsGap UpVTVTvTv Therapeutics2.2849 of 5 stars$19.36+3.1%$35.50+83.4%-15.5%$61.76M$1.02M-4.279BMEABiomea Fusion2.5336 of 5 stars$1.62-7.4%$23.91+1,375.9%-81.2%$60.87MN/A-0.4050Upcoming EarningsACHLAchilles TherapeuticsN/A$1.48flatN/AN/A$60.83MN/A-0.90250BDRXBiodexa Pharmaceuticals0.2181 of 5 stars$1.65-6.8%N/AN/A$60.30M$83,000.000.0020News Coverage Related Companies and Tools Related Companies Jasper Therapeutics Competitors Invivyd Competitors Viveon Health Acquisition Competitors Inozyme Pharma Competitors Janone Competitors Clearside Biomedical Competitors vTv Therapeutics Competitors Biomea Fusion Competitors Achilles Therapeutics Competitors Biodexa Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIVI) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredTrump’s treachery Intuitive Surgical at $1.99. Nvidia at $11. Shorting Fannie Mae months before collapse. That’s this analyst’s ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
